|
MM is a malignancy that primarily affects plasma cells, a vital component of the immune system found in bone marrow. Proper calcium regulation is a key factor in managing bone health and cellular function in MM patients. Dysregulation of calcium levels not only worsens the severity of MM but also contributes to a range of serious complications, significantly impacting patient outcomes.
As the second most common hematological malignancy, MM is characterized by its relentless progression, frequent relapses, and high mortality rate. Current therapeutic approaches for MM often lead to three to four relapses over months or years, inevitably resulting in disease progression and death. One of the critical factors in MM progression is the imbalance in bone metabolism, where heightened osteoclast activity drives bone destruction, and diminished osteoblast function hampers bone formation. This imbalance accelerates disease progression. AIC Therapy plays a critical role in combatting MM progression by stimulating bone formation, reducing osteoclast activity, and inhibiting the growth of myeloma cells, ultimately aiding in preventing relapses and disease advancement. Furthermore, cancer cells manipulate calcium channels and transporters to circumvent normal calcium regulation, promoting MM progression. AIC therapy addresses this by triggering endogenous calcitonin, which enhances bone turnover and improves calcium transport to the bones, offering a potentially superior treatment option for managing MM. As a novel therapeutic approach, AIC therapy holds the potential to improve patient outcomes for those battling MM significantly. This newsletter explores how AIC therapy, by targeting critical aspects of bone health and calcium regulation, can elevate the quality of life for patients with this challenging disease.
|
